Faculty Opinions recommendation of Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG oncology/gynecologic oncology group study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726377012.793527326 ◽

2017 ◽

Author(s):

Katherine Fuh

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Randomized Phase Ii

Download Full-text

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.08.027 ◽

2018 ◽

Vol 151 (2) ◽

pp. 257-263 ◽

Author(s):

William P. Tew ◽

Michael W. Sill ◽

Joan L. Walker ◽

Angeles Alvarez Secord ◽

Albert J. Bonebrake ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Randomized Phase Ii

Download Full-text

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.06.009 ◽

2012 ◽

Vol 127 (1) ◽

pp. 70-74 ◽

Author(s):

Russell J. Schilder ◽

William E. Brady ◽

Heather A. Lankes ◽

James V. Fiorica ◽

Mark S. Shahin ◽

...

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma

Download Full-text

Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.07.015 ◽

2020 ◽

Vol 159 (1) ◽

pp. 79-87

Author(s):

Krishnansu S. Tewari ◽

Michael W. Sill ◽

Robert L. Coleman ◽

Carol Aghajanian ◽

Robert Mannel ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Phase Ii ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Randomized Phase Ii

Download Full-text

A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.02.019 ◽

2012 ◽

Vol 125 (2) ◽

pp. 367-371 ◽

Author(s):

Don S. Dizon ◽

John A. Blessing ◽

Richard T. Penson ◽

Richard D. Drake ◽

Joan L. Walker ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma ◽

Platinum Resistant

Download Full-text

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.03.023 ◽

2012 ◽

Vol 125 (3) ◽

pp. 635-639 ◽

Author(s):

Michael A. Gold ◽

William E. Brady ◽

Heather A. Lankes ◽

Peter G. Rose ◽

Joseph L. Kelley ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma

Download Full-text

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.12.008 ◽

2019 ◽

Vol 152 (3) ◽

pp. 548-553 ◽

Author(s):

Ursula A. Matulonis ◽

Michael W. Sill ◽

Vicky Makker ◽

David G. Mutch ◽

Jay W. Carlson ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Primary Peritoneal Cancer ◽

Peritoneal Cancer ◽

Randomized Phase Ii

Download Full-text

Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)

Annals of Oncology ◽

10.1093/annonc/mdq401 ◽

2011 ◽

Vol 22 (3) ◽

pp. 636-642 ◽

Author(s):

H. Nomura ◽

D. Aoki ◽

F. Takahashi ◽

N. Katsumata ◽

Y. Watanabe ◽

...

Keyword(s):

Endometrial Carcinoma ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Randomized Phase Ii

Download Full-text

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.12.018 ◽

2014 ◽

Vol 132 (3) ◽

pp. 526-530 ◽

Author(s):

Lainie P. Martin ◽

Michael Sill ◽

Mark S. Shahin ◽

Matthew Powell ◽

Paul DiSilvestro ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma

Download Full-text

Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.09.015 ◽

2005 ◽

Vol 96 (1) ◽

pp. 67-71 ◽

Author(s):

David Scott Miller ◽

John A. Blessing ◽

Steven Waggoner ◽

Jeanne Schilder ◽

Joel Sorosky ◽

...

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma ◽

Platinum Resistant

Download Full-text

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2008.01.009 ◽

2008 ◽

Vol 109 (2) ◽

pp. 182-186 ◽

Author(s):

Susan C. Modesitt ◽

Michael Sill ◽

James S. Hoffman ◽

David P. Bender

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Peritoneal Carcinoma ◽

Oncology Group Study ◽

Primary Peritoneal Carcinoma

Download Full-text